This study tests how safe and effective a medicine called lorundrostat is for people with high blood pressure and kidney disease. Lorundrostat is used with another medicine called SGLT2 inhibitor (helps lower blood sugar) in this research. The study is randomized (participants are randomly assigned to groups) and double-blind (neither participants nor researchers know who gets the real medicine or a placebo, which is a fake pill). It has two treatment periods of 4 weeks each, with a 4-week break in between. Participants must be at least 18 years old, have high blood pressure, and kidney disease with protein in their urine. They must already be taking a medicine called ACEi or ARB for at least two months. The study will last for several weeks, including screening and treatment periods.

• The study lasts for several weeks, including screening, treatment, and breaks.
• Participants must be adults with specific health conditions.
• Participants will be randomly assigned to different treatment groups.